37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
Iwata H, Im S, Sohn J, Jung K, Im Y, Lee K, Inoue K, Tamura K, Wong A, Emens L, Barrios C, Adams S, Schneeweiss A, Diéras V, Winer E, Chui S, Henschel V, Rugo H, Loi S, Schmid P. 37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries. Annals Of Oncology 2019, 30: ix13-ix14. DOI: 10.1093/annonc/mdz418.Peer-Reviewed Original ResearchTriple-negative breast cancerAdvanced triple-negative breast cancerGenentech/RochePD-L1 expressionPD-L1Bristol-Myers SquibbF. Hoffmann-La RocheDaiichi SankyoBoehringer IngelheimHoffmann-La RocheSeattle GeneticsRoche/GenentechTumor-infiltrating immune cellsBreast Cancer Research FoundationECOG PS 0Key secondary endpointPD-L1 positivityNew safety signalsPD-L1 testingCo-primary endpointsEli LillyCancer Research FoundationNational Cancer InstituteMedical writing assistanceMedical Research Council289TiP ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer
Ignatiadis M, McArthur H, Bailey A, Martinez J, de Azambuja E, Metzger O, Lai C, Franzoi M, Goulioti T, Daly F, Bouhlel A, Balta V, Maetens M, Viale G, André B, DuFRane C, Nguyen D, Gelber R, Piccart M, Winer E. 289TiP ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer. Annals Of Oncology 2019, 30: v97. DOI: 10.1093/annonc/mdz240.112.Peer-Reviewed Original ResearchTriple-negative breast cancerInvasive disease-free survivalEarly-stage triple-negative breast cancerStage triple-negative breast cancerBreast International GroupNegative breast cancerBreast cancerAdjuvant chemotherapyPD-L1Seattle GeneticsRoche/GenentechMetastatic triple-negative breast cancerRoche-GenentechJules BordetOperable stage IIRandomized phase 3Same chemotherapy regimenStandard adjuvant chemotherapyCentral pathology reviewDisease-free survivalPD-L1 statusPhase 3 trialPhase III studyLymph node statusPD-L1 antibodiesLBA20 Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios C, Iwata H, Dieras V, Winer E, Kockx M, Peeters D, Chui S, Lin J, Duc A, Viale G, Molinero L, Emens L. LBA20 Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Annals Of Oncology 2019, 30: v858-v859. DOI: 10.1093/annonc/mdz394.009.Peer-Reviewed Original ResearchF. Hoffmann-La Roche LtdBiomarker-evaluable populationGenentech/RocheOverall percentage agreementMetastatic triple-negative breast cancerPD-L1 statusPD-L1F. Hoffmann-La RocheBristol-Myers SquibbDaiichi SankyoPercentage agreementOS benefitHoffmann-La RocheRoche/GenentechEli LillyPD-L1 IHC assaysPD-L1 immunohistochemistry assaysIHC assaysBoehringer IngelheimBreast Cancer Research FoundationSeattle GeneticsTriple-negative breast cancerNegative percentage agreementGreater clinical benefitPositive percentage agreement